表紙
市場調査レポート

細胞バンキングの新しい動向

Emerging Trends in Cell Banking

発行 Technical Insights (Frost & Sullivan) 商品コード 322315
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
細胞バンキングの新しい動向 Emerging Trends in Cell Banking
出版日: 2014年12月29日 ページ情報: 英文 60 Pages
概要

当レポートでは、マスターセルバンク(MCB)およびワーキングセルバンク(WCB)の新しい動向について調査し、技術の能力とバリューチェーン、市場成長への各種影響因子の分析、技術導入および技術開発の評価と技術・製品・サービスディベロッパーへの提言、特許、主な連絡先のデータなどをまとめています。

第1章 エグゼクティブ・サマリー

  • 調査範囲
  • 調査手法
  • 重要な調査結果

第2章 技術概要および動向

  • 技術概要
  • 技術プロセスの概要
  • 技術バリューチェーン
  • 技術能力

第3章 影響評価および分析

  • 重要な技術革新の市場への影響
  • 技術の市場への影響

第4章 技術革新の普及およびニーズ評価

  • 技術導入サイクル

第5章 機会の評価およびロードマッピング

  • シナリオモデリングおよび新しい市場機会
  • 需要サイド分析
  • バイオ医薬品事業者は自社の細胞株を維持し、当たらし細胞株の開発を行うためCMOとの提携を拡大
  • 企業プロファイル

第6章 主な連絡先・特許・意思決定支援データベース

  • 主な連絡先
  • 特許
  • DSD(意思決定支援データベース):政府医療費
  • DSD(意思決定支援データベース):医薬品R&D支出と医薬品市場における割合
  • DSD(意思決定支援データベース):医薬品R&D支出
  • DSD(意思決定支援データベース):総医療費
  • DSD(意思決定支援データベース):バイオテクノロジーR&Dへのベンチャーキャピタル投資額
  • 免責事項

第7章 FROST & SULLIVANについて

目次
Product Code: D567-TI

Trends in Master and Working Cell Baking

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of most operational challenges. Indeed, cultured cells are frequently used to generate monoclonal antibodies (MAbs), enzymes, or substrates to be then utilized in other types of tests, such as ligand binding and enzymatic assays, thereby requiring distinct characterization and control measures to guarantee functional reliability over time.

The extreme sensitivity of cellular components to different chemical and physical elements and the possibility of alterations in the proteome expression profiles hold significant importance in assessing biopharmaceutical products. Therefore, the need for homogeneous, stable cell banks capable of safeguarding starting cellular material is substantial to perform reliable cell-based assays. Master and working cell banks (MCBs and WCBs) are established with the aim to provide a continuous source of viable cells that allow to generate accurate results for specific test methods.

This research service brings out the emerging trends in MCBs and WCBs on a global scale, through a detailed description of:

  • The technology capability and value chain; analysis of global technology trends.
  • An impact analysis of major drivers, restraints, and challenges influencing the growth of cell banks by timeframes.
  • An assessment of technology adoption and development, by region, demand side analysis, and recommendations for technology/product/services developers.
  • An evaluation of scenario modelling and emerging opportunities in MCBs and WCBs, technology management strategies and technology application roadmap.
  • A list of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Research Scope
  • 2. Research Methodology
  • 3. Key Findings

2. TECHNOLOGY SNAPSHOT AND TRENDS

Technology Snapshot and Trends

  • 1. Technology Overview
  • 2. Technology Process Overview
  • 3. Technology Value Chain
  • 4. Technology Capability
  • 5. Technology Capability
  • 6. Technology Capability
  • 7. Technology Capability

3. IMPACT ASSESSMENT AND ANALYSIS

Impact Assessment and Analysis

  • 1. Market Impact of Key Innovations
  • 2. Market Impact of Key Innovations
  • 3. Market Impact of Technology
  • 4. Market Impact of Technology

4. DIFFUSION OF INNOVATIONS AND NEEDS ASSESSMENT

Diffusion of Innovations and Needs Assessment

  • 1. Technology Adoption Cycle
  • 2. Technology Adoption Cycle
  • 3. Technology Adoption Cycle
  • 4. Technology Adoption Cycle
  • 5. Technology Adoption Cycle
  • 6. Technology Adoption Cycle
  • 7. Technology Adoption Cycle
  • 8. Technology Adoption Cycle
  • 9. Technology Adoption Cycle
  • 10. Technology Adoption Cycle
  • 11. Technology Adoption Cycle

5. OPPORTUNITY EVALUATION AND ROADMAPPING

Opportunity Evaluation and Roadmapping

  • 1. Scenario Modelling and Emerging Opportunities
  • 2. Demand Side Analysis
  • 3. Demand Side Analysis
  • 4. Biophramas are increasing their partnerships with CMOs, for storing their proprietary cell lines and the development of novel cell lines.
  • 5. Company Profiles (continued)
  • 6. Company Profiles (continued)
  • 7. Company Profiles (continued)
  • 8. Company Profiles (continued)
  • 9. Company Profiles (continued)

6. KEY CONTACTS, KEY PATENTS, ANDDECISION SUPPORT DATABASE

Key Contacts, Key Patents, andDecision Support Database

  • 1. Key Contacts
  • 2. Key Contacts (continued)
  • 3. Key Contacts (continued)
  • 4. Key Contacts (continued)
  • 5. Patents
  • 6. Patents (continued)
  • 7. DSD-Government Healthcare Expenditure (Billion USD)
  • 8. DSD-Pharmaceutical R&D Expenditure as a Percentage of Pharmaceutical Market
  • 9. DSD-Pharmaceutical R&D Expenditure (Million USD)
  • 10. DSD-Total Healthcare Expenditure (Billion USD)
  • 11. DSD-Venture Capital Investment in Biotech R&D (Million USD)
  • 12. Legal Disclaimer

7. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. Who is Frost & Sullivan
  • 2. What Makes Us Unique
  • 3. TEAM Methodology
  • 4. Our Global Footprint 40+ Offices
Back to Top